Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Next Previous
Trial Profile

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Carcinoma; Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DUO-E
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 10 Feb 2026 According to AstraZeneca media release, based on this study, Imfinzi combination with carboplatin and paclitaxel is approved in China in Jan 2026, for the 1st-line treatment of adult patients with primary advanced or recurrent endometrial cancer.
  • 28 Jul 2025 According to an AstraZeneca media release, Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer in US and EU.
  • 20 Nov 2024 Planned End Date changed from 14 Aug 2027 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top